The Real-World Safety and Efficacy of Directly Acting Antiviral Therapy for the Treatment of Patients with Hepatitis C Infection and Decompensated Cirrhosis - Egyptian Knowledge Bank - troweb

59310

The Real-World Safety and Efficacy of Directly Acting Antiviral Therapy for the Treatment of Patients with Hepatitis C Infection and Decompensated Cirrhosis

Article

Last updated: 01 Jan 2025

Overview Similar Items

Article

Outcomes of direct acting antiviral therapy for treatment of HCV infection in patients with decompensated liver cirrhosis

Article

Safety and Efficacy of Direct Acting Antivirals for Hepatitis C Virus Infection in Thalassemic Patients and Its Effect on Transfusion Requirements

Article

Outcome of Decompensated Hepatitis C Virus Cirrhotic Patients Treated with Direct Acting Antiviral Drugs

Article

SAFETY AND EFFICACY OF DIRECTLY ACTING ANTIVIRAL DRUGS IN TREATMENT OF CHRONIC HCV EGYPTIAN PATIENTS

Article

Tolerance and Effectiveness of Oral Direct Acting Antivirals in Treatment of HCV Egyptian patients with Decompensated Liver Cirrhosis

Article

Evaluation of Ledipasvir plus Sofosbuvir for Treatment of Compensated and Decompensated HCV Cirrhotic Patients

Article

Long-term Follow-up of Chronic Hepatitis C Patients Treated by Direct- Acting Antivirals

Article

Efficacy of Sofosbuvir-Daclatasvir in Treatment of Chronic Hepatitis C Virus Infection

Article

Efficacy and Safety of Ombitasvir, Paritaprevir and Ritonavir plus Ribavirin in Hepatitis C Genotype-4 Patients on Hemodialysis

Article

Safety and Efficacy of Direct Acting Antivirals (Sofosbuvir & Daclatasvir) in treatment of Chronic HCV in HIV-HCV Co-Infected Egyptian Patients